RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:93921

Full schwannomatosis

low confidenceDisorder

Also known as: Full NF3 · Full SWN · Full neurofibromatosis type 3 · Neurilemmomatosis · Nonmosaic schwannomatosis

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

2,390

Trials

10

Interventional, condition-specific

Researchers

1,107

Distinct authors in sample

Gene link

LZTR1

Definitive

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare form of neurofibromatosis characterized by the development of multiple schwannomas (nerve sheath tumors), without involvement of the vestibular nerves, and often associated with chronic pain. Dysesthesia and paresthesia may also be present. Common localizations include the spine, peripheral nerves, and the cranium.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (6)

NF3 · Neurinomatosis · Schwannomatosis · neurilemmomatosis · neurofibromatosis type 3 · schwannomatosis

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Definitive — LZTR1

  2. LiteraturePresent

    2,390 matched papers (1,790 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    10 matched on ClinicalTrials.gov (6 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (LZTR1).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

2,390

2,390 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

2,390 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

1,790 in the last 10 years · low confidence

Phrase hits: 2,390 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,107

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Kalamarides M13 papers · 2026

    Department of Neurosurgery, Bâtiment Babinski, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Universités, 47-83 boulevard de l'Hôpital, 75013, Paris, France.

    Papers in Europe PMC
  2. 02
    Evans DG12 papers · 2026

    Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK.

    Papers in Europe PMC
  3. 03
    Plotkin SR12 papers · 2026

    From Massachusetts General Hospital and Harvard Medical School (S.R.P., V.L.M.) and the Dana-Farber Cancer Institute (G.F., L.T.) - all in Boston; the NYU Grossman School of Medicine (K.H.Y.) and the Children's Tumor Foundation (A.B.) - both in New York; the University of California, Los Angeles, Los Angeles (P.L.N.); the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami (C.T.D.); the Mayo Clinic, Rochester, MN (D.B.-V.); and Johns Hopkins University, Baltimore (J.O.B.).

    Papers in Europe PMC
  4. 04
    Smith MJ9 papers · 2026

    Geoffrey Jefferson Brain Research Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.

    Papers in Europe PMC
  5. 05
    Peyre M8 papers · 2026

    Department of Neurosurgery, Bâtiment Babinski, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Universités, 47-83 boulevard de l'Hôpital, 75013, Paris, France. matthieu.peyre@aphp.fr.

    Papers in Europe PMC
  6. 06
    Blakeley JO7 papers · 2026

    From Massachusetts General Hospital and Harvard Medical School (S.R.P., V.L.M.) and the Dana-Farber Cancer Institute (G.F., L.T.) - all in Boston; the NYU Grossman School of Medicine (K.H.Y.) and the Children's Tumor Foundation (A.B.) - both in New York; the University of California, Los Angeles, Los Angeles (P.L.N.); the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami (C.T.D.); the Mayo Clinic, Rochester, MN (D.B.-V.); and Johns Hopkins University, Baltimore (J.O.B.).

    Papers in Europe PMC
  7. 07
    Tamura R7 papers · 2026

    Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan.

    Papers in Europe PMC
  8. 08
    King AT6 papers · 2026

    Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Manchester, UK.

    Papers in Europe PMC
  9. 09
    Toda M6 papers · 2026

    Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan.

    Papers in Europe PMC
  10. 10
    Pathmanaban ON5 papers · 2026

    Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Manchester, UK.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

10

interventional trials for this specific condition

10 interventional trials matched this specific condition name; 6 currently recruiting in our sample.

Data as of 27 July 2026

10 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 91.7th percentile).

low confidence · 91.7th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

10 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Full schwannomatosis" OR "Full NF3" OR "Full SWN" OR "Full neurofibromatosis type 3" OR "Neurilemmomatosis" OR "Nonmosaic schwannomatosis" OR "Neurinomatosis" OR "Schwannomatosis" OR "neurofibromatosis type 3"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Full schwannomatosis" OR "Full NF3" OR "Full SWN" OR "Full neurofibromatosis type 3" OR "Neurilemmomatosis" OR "Nonmosaic schwannomatosis" OR "Neurinomatosis" OR "Schwannomatosis" OR "neurofibromatosis type 3" OR "LZTR1"

Recall-expansion terms: LZTR1

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 10 interventional · 1 observational · 1 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: NF3

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (2390) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T04:30:44.106Z